Fig. 5.

Median progression-free survival (PFS) for cyclin-dependent kinase 4/6 inhibitor treatment are presented in the third-line plus (3L+) setting. Each included patient population is presented along the X-axis with a unique reference number. The size of each bubble represents the sample size. Data were further grouped and color coded by the treatment received prior to cyclin-dependent kinase 4/6 inhibitor treatment. A complete list of included studies and reported PFS are presented in Table 3. #L number of lines of therapy, 4L fourth line, 6L sixth line, CT chemotherapy, ET endocrine therapy, NR not reported, Ref # reference number